Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants With Generalized Myasthenia Gravis

NCT05681715 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT05681715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05681715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants With Generalized Myasthenia Gravis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
April 17, 2023
Completion date
April 23, 2024
Enrollment
62 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis